Literature DB >> 2181028

A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

J T Grayston1, L A Campbell, C C Kuo, C H Mordhorst, P Saikku, D H Thom, S P Wang.   

Abstract

Chlamydia pneumoniae strain TWAR, the new third species of Chlamydia, is a common cause of pneumonia and other acute respiratory tract infections. About 10% of hospitalized and outpatient pneumonia cases have been associated with TWAR infection. TWAR is among the four or five most commonly identified causes of all pneumonia. Most TWAR infections are mild or asymptomatic, but occasionally severe pneumonia with death has been observed. Laboratory diagnosis is not generally available. Vigorous treatment with tetracycline or erythromycin is recommended. Both epidemic and endemic infections have been described in North America and the Nordic Countries. Population prevalence antibody studies suggest that TWAR infection is wide-spread throughout the world, that nearly everyone is infected and reinfected during their life-time, and that infection is common in all ages except those less than 5 years in temperate zone countries. The infection is transmitted from person to person, apparently with a long incubation period.

Entities:  

Mesh:

Year:  1990        PMID: 2181028     DOI: 10.1093/infdis/161.4.618

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  147 in total

1.  Optimizing culture of Chlamydia pneumoniae by using multiple centrifugations.

Authors:  J M Pruckler; N Masse; V A Stevens; L Gang; Y Yang; E R Zell; S F Dowell; B S Fields
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

Review 2.  How can a causal role for small bacteria in chronic inflammatory arthritides be established or refuted?

Authors:  D Taylor-Robinson; A Keat
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

3.  Mutagenesis and functional reconstitution of chlamydial major outer membrane proteins: VS4 domains are not required for pore formation but modify channel function.

Authors:  E S Hughes; K M Shaw; R H Ashley
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

Review 4.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

5.  Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults.

Authors:  Robert M Wadowsky; Elias A Castilla; Stella Laus; Anita Kozy; Robert W Atchison; Lawrence A Kingsley; Joel I Ward; David P Greenberg
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

6.  Serological cross-reactions between Bartonella and Chlamydia species: implications for diagnosis.

Authors:  M Maurin; F Eb; J Etienne; D Raoult
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

7.  The Role of Chlamydia in Upper Respiratory Tract Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

8.  Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis.

Authors:  L A Jackson; L A Campbell; R A Schmidt; C C Kuo; A L Cappuccio; M J Lee; J T Grayston
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

9.  Outbreak of Chlamydia pneumoniae infection in four farm families.

Authors:  C H Mordhorst; S P Wang; J T Grayston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

10.  Association between Chlamydia pneumoniae IgG antibodies and migraine.

Authors:  QiHong Lu; Jinzh Xu; HongYan Liu
Journal:  J Headache Pain       Date:  2009-02-24       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.